NCT05354050View on ClinicalTrials.gov

Pharmacokinetic Study of DARE-BV1

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 3, 2020

Primary Completion Date

November 18, 2020

Study Completion Date

December 2, 2020

Conditions
Bacterial Vaginosis
Interventions
DRUG

DARE-BV1

2% Clindamycin 100 MG

Trial Locations (1)

78209

ICON Early Phase Services, LLC, San Antonio

Sponsors
All Listed Sponsors
lead

Daré Bioscience, Inc.

INDUSTRY